.png){kind=icon}
返回
A
Alfredo Addeo
University of Bern
48H指数
376论文数
7.3K被引数
收录论文 125
发表时间
.png){kind=icon}
Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – a multicenter single arm open label phase II trial (SAKK 15/19)胸腺放射治疗联合Durvalumab维持治疗，在一线Carboplatin和Etoposide联合Durvalumab治疗后的广泛期小细胞肺癌（ES-SCLC）——一项多中心单臂开放标签II期临床试验（SAKK 15/19）。.png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14性别特异性的疗效和安全性结局：在接受新辅助治疗的可切除III期非小细胞肺癌（NSCLC）患者中的联合分析——SAKK试验16/96、16/00、16/01、16/08和16/14.png)
ESMO OpenOAAI
ESMO OpenIF8.3
OAAI分享收藏Rationale and design of the AUSTRAL trial: An open-label, multicenter, phase II study evaluating radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses and/or oligometastases after the PACIFIC regimen.AUSTRAL试验的原理与设计：一项开放标签、多中心、II期研究，旨在评估在完成PACIFIC方案治疗后出现胸腔内复发和/或寡转移的III期NSCLC患者中，采用放疗后序贯度鲁瓦木单抗（MEDI4736）和塞拉拉塞替（AZD6738）的治疗效果。Clinical Lung Cancer
Clinical Lung CancerIF3.3
PREAI
分享收藏Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment-A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report接受新辅助治疗后未进行根治性手术的可切除III期NSCLC患者的结局——SAKK试验16/96、16/00、16/01、16/08和16/14的回顾性分析：简报OAAI
OAAI分享收藏分享收藏